Kazia KZIA 深 沪
已收盘 07-02 16:00:00 美东时间
13.25
-0.140
-1.05%
华盛通- 最 高14.15
- 今 开13.63
- 成交量 11.61万股
- 最 低 13.14
- 昨 收 13.39
- 总市值 1.51亿
- 52周最高 17.40
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 4.86
- 委 比 -48.72%
- 总股本 1142.69万
- 历史最高 744.50
- 量 比 0.82
- 振 幅 7.54%
- 历史最低 3.005
- 每 手 1
- 风险率 2.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $34.
07-01 19:36
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Lake Street Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $32
Lake Street initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $32.
06-11 22:53
Kazia Therapeutics任命资深交易专家James Levine为新任CFO
澳大利亚临床阶段肿瘤公司Kazia Therapeutics Limited宣布，任命James Levine为首席财务官，自2026年6月1日起生效。L...
06-02 22:48
Kazia Therapeutics Appoints James Levine As CFO, Effective June 1
Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies."James has built an impressive career leading financial strategy,
06-02 19:39
Kazia Therapeutics Expands Enrollment In Phase 1b Trial For Breast Cancer Treatment Paxalisib
Based on continued encouraging safety, tolerability and clinical activity data observed to date, planned enrollment has increased from 12 to 36 patients.The expansion is intended to further evaluate the safety,
05-26 19:36
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome tr...
04-14 05:05
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Kazia Therapeutics Announces Three Patients With Metastatic Triple-Negative Breast Cancer With Paxalisib-Based Regimens Have Demonstrated Meaningful Clinical Responses In Phase 1b Trial Of Paxalisib In Combination With Pembrolizumab And Chemotherapy
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV),
01-27 21:11
